HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc06-1576v1 30/5/1056    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwarzenberg, S. J. Articles by Moran, A. Search for Related Content PubMed PubMed Citation Articles by Schwarzenberg, S. J. Articles by Moran, A. Social Bookmarking                What's this?

Microvascular Complications in Cystic Fibrosis–Related Diabetes

¹ Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota
² Department of Biostatistics, University of Minnesota, Minneapolis, Minnesota
³ Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota
⁴ Department of Neurology, University of Minnesota, Minneapolis, Minnesota

Address correspondence and reprint requests to Antoinette Moran, MD, Pediatric Endocrinology MMC 404, University of Minnesota, 516 Delaware St., SE, Minneapolis, MN 55454. E-mail: moran001{at}umn.edu

OBJECTIVE—The incidence of cystic fibrosis–related diabetes (CFRD) and the prevalence of diabetic microvascular complications were determined at the University of Minnesota.

RESEARCH DESIGN AND METHODS—Cystic fibrosis patients have undergone annual oral glucose tolerance testing since 1990. Database review was performed to determine diabetes duration and the results of annual urine albumin-to-creatinine ratio (U_alb:Cr) screening and dilated retinal exams. In addition, 59 individuals underwent detailed retinopathy, nephropathy, neuropathy, and gastroenterpathy screening.

RESULTS—During 1990–2005, 775 patients aged 6 years were followed. CFRD was diagnosed by an oral glucose tolerance test or fasting hyperglycemia in 285 subjects (52% female), 64% of whom had fasting hyperglycemia. Most patients with CFRD without fasting hyperglycemia progressed to CFRD with fasting hyperglycemia over time. No subject with CFRD without fasting hyperglycemia had retinopathy or abnormal U_alb:Cr. In CFRD subjects with fasting hyperglycemia and diabetes for 10 years, 14% had microalbuminuria and 16% had retinopathy. Autonomic neuropathy and gastrointestinal symptoms each were seen in 52% and somatic abnormalities in 22% of patients with or without fasting hyperglycemia.

CONCLUSIONS—Diabetic microvascular complications occur in CFRD, although the prevalence of retinopathy and nephropathy appears to be less than that found in other forms of diabetes. Annual complication screening should occur after known diabetes duration of 5 years in patients with CFRD with fasting hyperglycemia.

Abbreviations: CFRD, cystic fibrosis–related diabetes

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. C L. Hewer and J. Tyrrell Cystic fibrosis and the transition to adult health services Arch. Dis. Child., October 1, 2008; 93(10): 817 - 821. [Full Text] [PDF]